Tango Therapeutics (TNGX) & Its Competitors Critical Contrast

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Tango Therapeutics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Tango Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tango Therapeutics N/A -30.34% -28.28%
Tango Therapeutics Competitors -12,516.26% -215.91% -31.70%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Tango Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tango Therapeutics 2 2 13 0 2.65
Tango Therapeutics Competitors 9920 15327 45725 1601 2.54

Tango Therapeutics presently has a consensus price target of $48.17, suggesting a potential upside of 120.04%. As a group, “Biotechnology” companies have a potential upside of 108.55%. Given Tango Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tango Therapeutics is more favorable than its rivals.

Valuation and Earnings

This table compares Tango Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tango Therapeutics $62.38 million -$101.59 million -15.98
Tango Therapeutics Competitors $738.69 million $10.07 million -18.46

Tango Therapeutics’ rivals have higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Tango Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Tango Therapeutics’ rivals have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.

Summary

Tango Therapeutics beats its rivals on 9 of the 13 factors compared.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.